XTL Biopharmaceuticals Ltd: Form 20-F for the period ended Dec 31, 2019
Filed with the SEC on Mar 12, 2020 and accepted by EDGAR at Mar 12, 2020, 19:44 ET.
Sections
Sections are extracted only from 10-K and 10-Q reports. Read this filing’s documents on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2019-12-31. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Operating income | 12 months2019-01-01 to 2019-12-31 | −$842.0k | ifrs-full:ProfitLossFromOperatingActivities |
| Net income | 12 months2019-01-01 to 2019-12-31 | −$1.3m | ifrs-full:ProfitLoss |
| Operating cash flow | 12 months2019-01-01 to 2019-12-31 | −$908.0k | ifrs-full:CashFlowsFromUsedInOperatingActivities |
| Capital expenditure | 12 months2019-01-01 to 2019-12-31 | $2.0k | ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities |
| Cash and equivalents | At period end2019-12-31 | $4.5m | ifrs-full:CashAndCashEquivalents |
| Current assets | At period end2019-12-31 | $6.8m | ifrs-full:CurrentAssets |
| Total assets | At period end2019-12-31 | $7.2m | ifrs-full:Assets |
| Shareholders' equity | At period end2019-12-31 | $7.0m | ifrs-full:Equity |
| Shares outstanding | At period end2019-12-31 | 514,205,799 shares | dei:EntityCommonStockSharesOutstanding |
Source: SEC EDGAR, the filing index for accession 0001213900-20-006104. Last ingested by Listed: Oct 24, 2026, 15:02 ET. Listed shows no prices and gives no investment advice.